Cancer News and Research

Latest Cancer News and Research

Senate Health Committee likely to hold hearing on new mammogram guidelines

Roll Call reports that 22 senators have written the Senate Health, Education, Labor and Pensions Committee asking its leaders to hold hearings on controversial new mammogram guidelines. "The letter came less than a week after the U.S. Preventive Services Task Force recommended looser guidelines for breast cancer screenings. The task force suggested that women wait until they turn 50 to begin screening and then undergo one mammogram every two years instead of every year."

25 Nov 2009

Johnson & Johnson Focused Funding grant for research on brain cell damage in PD

‏Dr. Sarit Larisch, Head of the Cell Death Research Laboratory and senior lecturer at the University of Haifa, has been awarded the prestigious Johnson & Johnson Focused Funding grant for her research exploring the cause of brain cell damage in Parkinson's disease.

25 Nov 2009

Novartis to terminate its research collaboration agreement with Idera Pharmaceuticals

Idera Pharmaceuticals, Inc., today announced that Novartis will terminate its research collaboration agreement with the Company, effective as of February 21, 2010.

25 Nov 2009

Human Genome Sciences submits BLA for ZALBIN

Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.

25 Nov 2009

Smoothie Factory supports Chronic Disease Fund’s mission with holiday fundraising program

More than 14-million Americans, with chronic or life altering diseases and cancer, can’t afford the medication they need because of the high out-of-pocket costs associated with their insurance coverage. That’s why the Chronic Disease Fund, a nonprofit organization, provides financial help to seriously ill Americans so they can get the medications they need to live without the fear of debt.

25 Nov 2009

Seven-day event focuses on nuclear medicine, molecular imaging, nanomedicine and clinical trials

SNM will hold its Conjoint Mid-Winter Meetings Jan. 27-Feb. 2, 2010, at the Albuquerque Convention Center in Albuquerque, N.M. This year, SNM joins its annual Mid-Winter Educational Symposium with the 2010 Annual Meeting and Educational Symposium of the American College of Nuclear Medicine (ACNM), the Nanomedicine and Molecular Imaging Summit and the Clinical Trials Network Community Workshop.

25 Nov 2009

'Suicide gene E' reduces potent drug dosage in cancer patients

Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the death of tumour cells derived from breast, lung and colon cancer, and prevents their growth. The importance of this new gene is that its use to fight cancer can reduce the potent drugs that are currently used, so that could mean more effective treatment for cancer.

25 Nov 2009

2010 promises to continue acquisition activity as companies seek ways to bolster their pipelines and portfolios

In the past year, drug makers' thirst for innovation combined with small companies' dwindling operating capital to drive merger and acquisition activity. At the high end of the scale, consolidation among industry leaders created some of the richest pharmaceutical mergers in history.

25 Nov 2009

Tulane University surgeon performs a new form of endoscopic surgery

Tulane University School of Medicine surgeon Dr. Emad Kandil is one of the first in the country to perform a new form of endoscopic surgery that uses a small incision under the arm to remove all or a portion of the thyroid or parathyroid glands without leaving a scar on the neck.

25 Nov 2009

SBI urges Congress to exclude the USPSTF guidelines from health care legislation

Several sections of Senate health care reform legislation contain language stipulating that insurance entities such as private insurers, Medicare and Medicaid would only be required to cover services receiving a specific grade from the U.S. Preventative Services Task Force. Presently, this would exclude mammography services for women 40-49, would only require coverage of biennial (every other year) coverage for women 50-74, and exclude coverage for those 74 and older.

25 Nov 2009

Study may pave way for potential drug targets in lung cancer treatment

Researchers from Boston University School of Medicine (BUSM) and the Boston University Biomedical Engineering Department have identified a number of proteins whose activation allows them to distinguish between cancer and normal cells with almost 97 percent accuracy.

25 Nov 2009

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The

25 Nov 2009

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that presentations of clinical data for three product candidates employing its Targeted Antibody Payload (TAP) technology will be made at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition to be held in New Orleans, LA, on December 5-8, 2009.

25 Nov 2009

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Meeting (ASH) to be held in New Orleans, LA ,December 5-8, 2009. An oral presentation will highlight results from an ongoing clinical Phase I monotherapy safety study in adults with acute myeloid leukemia (AML).

25 Nov 2009

Researchers uncover atomic-level action of ring-shaped protein motors

The atomic-level action of a remarkable class of ring-shaped protein motors has been uncovered by researchers with the Lawrence Berkeley National Laboratory (Berkeley Lab) using a state-of-the-art protein crystallography beamline at the Advanced Light Source (ALS).

25 Nov 2009

Health watch: When you eat just as vital to what you eat

When you eat may be just as vital to your health as what you eat, found researchers at the Salk Institute for Biological Studies. Their experiments in mice revealed that the daily waxing and waning of thousands of genes in the liver—the body's metabolic clearinghouse—is mostly controlled by food intake and not by the body's circadian clock as conventional wisdom had it.

25 Nov 2009

Emerging cancer vaccines: Forecasts, new developments and pipeline analysis

The H1N1 vaccine has spurred media interest in vaccines, as well as predictions of vaccines for a host of new diseases. According to Kalorama Information, certain cancers may be added to the list of diseases for which vaccinations will be employed.

25 Nov 2009

New Brunswick's colorectal cancer screening program lauded by CCAC

The Colorectal Cancer Association of Canada (CCAC) applauds the decision of the New Brunswick's Minister of Health Mary Schryer to implement a province wide colorectal cancer screening program and to provide funding for Avastin (bevacizumab) for patients with metastatic colorectal cancer.

25 Nov 2009

Study: GSTP gene protects against bowel cancer

CANCER RESEARCH UK scientists have shown that deleting a single gene can increase the average number of tumours in the bowel by 50-fold, according to research published in PNAS today.

25 Nov 2009

Alpha-fetoprotein, a well-tolerated agent for treatment and prevention of breast cancer

Researchers have found that hormones produced during pregnancy induce a protein that directly inhibits the growth of breast cancer. This protein, alpha-fetoprotein (AFP), may serve as a viable, well-tolerated agent for the treatment and prevention of breast cancer, according to findings published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

25 Nov 2009

Cancer News and Research

Latest Cancer News and Research

Senate Health Committee likely to hold hearing on new mammogram guidelines

Johnson & Johnson Focused Funding grant for research on brain cell damage in PD

Novartis to terminate its research collaboration agreement with Idera Pharmaceuticals

Human Genome Sciences submits BLA for ZALBIN

Smoothie Factory supports Chronic Disease Fund’s mission with holiday fundraising program

Seven-day event focuses on nuclear medicine, molecular imaging, nanomedicine and clinical trials

'Suicide gene E' reduces potent drug dosage in cancer patients

2010 promises to continue acquisition activity as companies seek ways to bolster their pipelines and portfolios

Tulane University surgeon performs a new form of endoscopic surgery

SBI urges Congress to exclude the USPSTF guidelines from health care legislation

Study may pave way for potential drug targets in lung cancer treatment

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Researchers uncover atomic-level action of ring-shaped protein motors

Health watch: When you eat just as vital to what you eat

Emerging cancer vaccines: Forecasts, new developments and pipeline analysis

New Brunswick's colorectal cancer screening program lauded by CCAC

Study: GSTP gene protects against bowel cancer

Alpha-fetoprotein, a well-tolerated agent for treatment and prevention of breast cancer

Cancer Research - Second Edition eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in